No statistically significant differences between groups at baseline. Results for normally distributed data are presented as the mean ± SD at each timepoint and as mean [95% CI] for change after 6 months. Non-normally distributed data are presented as median with interquartile range (25%, 75%). ‡ p-value for a modified intention to treat analysis using all available data. Student's t-test was used to compare changes between groups for normally distributed variables, and Wilcoxon rank sum test was used to compare changes between groups for variables that were not normally distributed. Treatment effect is mean [95% CI] for normally distributed endpoints and the net difference between median changes in each group for endpoints that were not normally distributed. ‡ ‡ p-value for imputation analyses. For normally distributed variables, multiple imputation was performed by replacing missing values with imputed values calculated over 100 iterations, using longitudinal mixed effects modeling, and discarding the first 10 iterations. The p-value is the average of the p-values from the individual runs of the multiply imputed data sets. The values in parentheses provide a range (2.5 th percentile, 97.5 th percentile) of the estimated effect sizes for the imputation analyses. For non-normally distributed endpoints, imputation analysis was performed by replacing the missing data for the 0 to 6 month changes using the median of the change in the combined groups. The p-value given is for Wilcoxon rank sum test for comparison of change between groups using the imputed data set. For these data, range of estimates is not available. Mean±SD IGF-1 Z-scores and IGF-1 levels (ng/mL) at each timepoint in the placebo group and the tesamorelin group (with sample sizes shown), along with IGF-1 Z-scores and levels at each timepoint for the two patients who received blinded dose reduction between the 3 and 6 month visits. IGF-1 levels were analyzed only after breaking the blind at the completion of the randomized study, when it was determined that both of these patients were in the tesamorelin group. There were no significant differences between treatment groups in IGF-1 or IGF-1 Z-score at baseline. Bivariate relationships were assessed using Spearman's rank correlation coefficient, as change in liver fat is not normally distributed. Multivariable regression analysis was performed to assess for significant differences in the slope of the relationship between the tesamorelin vs. placebo groups (i.e., randomization × xvariable term), and no significant interactions were found.
*M is insulin stimulated glucose uptake (mg/kg/min) during steady state (100-120 minutes) during euglycemic hyperinsulinemic clamp.
Abbreviations: HCL/W%: hepatic lipid-to-water percent; ALT: alanine aminotransferase; AST: aspartate aminotransferase.
Error bars are IQR. Sampling occurred every 20 minutes from 8pm to 7:40am. Sample size in the tesamorelin group is 25 at baseline and 21 at 6 months. Sample size in the placebo group is 20 at baseline and 15 at 6 months. Black circles indicate patients in the tesamorelin group and white circles those in the placebo group. ρ and P-value for Spearman regression. Thicker line represents Pearson regression line among all subjects. Thinner regression lines labeled (T) and (P) represent Pearson regression lines within each treatment group (tesamorelin and placebo, respectively). Multivariable regression analysis was performed to assess for significant differences in the slope of the relationship between the tesamorelin vs. placebo groups (i.e., randomization × Δ liver fat term), and the interaction was not significant. 
